In vivo incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells

G. Morstyn, T. Kinsella, C. S.K. Shan, J. Whang-Peng, A. Russo, J. B. Mitchell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bromodeoxyuridine (BUdR), a potential radiosensitizing drug, was given by intravenous infusion at 650-1000 mg/m2/day for up to 12 days. In vivo incorporation into human bone marrow was assayed by differential chromatid staining as well as by comparison of in vitro radiation survival curves of granulocyte-macrophage progenitor cells scored at both day 7 and day 14. Although a difference was found in the radiation survival of control (untreated) day-7 progenitor cells (Do = 1.39 Gy) and day-14 progenitor cells (Do = 0.89 Gy), a similar degree of in vitro radiosensitization was found for BUdR-treated bone marrow progenitor cells scored at day 7 and day 14. The culture technique provided a bioassay for the in vivo action of BUdR. BUdR treatment produced transient moderate myelosuppression that probably resulted from BUdR incorporation into normal marrow cells.

Original languageEnglish
Pages (from-to)289-294
Number of pages6
JournalExperimental Hematology
Volume13
Issue number4
Publication statusPublished - Aug 14 1985
Externally publishedYes

Fingerprint

Granulocyte-Macrophage Progenitor Cells
Bromodeoxyuridine
Bone Marrow
Stem Cells
Radiation
Radiation-Sensitizing Agents
Culture Techniques
Chromatids
Survival
Intravenous Infusions
Bone Marrow Cells
Biological Assay
Staining and Labeling

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

In vivo incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells. / Morstyn, G.; Kinsella, T.; Shan, C. S.K.; Whang-Peng, J.; Russo, A.; Mitchell, J. B.

In: Experimental Hematology, Vol. 13, No. 4, 14.08.1985, p. 289-294.

Research output: Contribution to journalArticle

@article{3fd76809115347eea90daf83d4cb8e9e,
title = "In vivo incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells",
abstract = "Bromodeoxyuridine (BUdR), a potential radiosensitizing drug, was given by intravenous infusion at 650-1000 mg/m2/day for up to 12 days. In vivo incorporation into human bone marrow was assayed by differential chromatid staining as well as by comparison of in vitro radiation survival curves of granulocyte-macrophage progenitor cells scored at both day 7 and day 14. Although a difference was found in the radiation survival of control (untreated) day-7 progenitor cells (Do = 1.39 Gy) and day-14 progenitor cells (Do = 0.89 Gy), a similar degree of in vitro radiosensitization was found for BUdR-treated bone marrow progenitor cells scored at day 7 and day 14. The culture technique provided a bioassay for the in vivo action of BUdR. BUdR treatment produced transient moderate myelosuppression that probably resulted from BUdR incorporation into normal marrow cells.",
author = "G. Morstyn and T. Kinsella and Shan, {C. S.K.} and J. Whang-Peng and A. Russo and Mitchell, {J. B.}",
year = "1985",
month = "8",
day = "14",
language = "English",
volume = "13",
pages = "289--294",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - In vivo incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells

AU - Morstyn, G.

AU - Kinsella, T.

AU - Shan, C. S.K.

AU - Whang-Peng, J.

AU - Russo, A.

AU - Mitchell, J. B.

PY - 1985/8/14

Y1 - 1985/8/14

N2 - Bromodeoxyuridine (BUdR), a potential radiosensitizing drug, was given by intravenous infusion at 650-1000 mg/m2/day for up to 12 days. In vivo incorporation into human bone marrow was assayed by differential chromatid staining as well as by comparison of in vitro radiation survival curves of granulocyte-macrophage progenitor cells scored at both day 7 and day 14. Although a difference was found in the radiation survival of control (untreated) day-7 progenitor cells (Do = 1.39 Gy) and day-14 progenitor cells (Do = 0.89 Gy), a similar degree of in vitro radiosensitization was found for BUdR-treated bone marrow progenitor cells scored at day 7 and day 14. The culture technique provided a bioassay for the in vivo action of BUdR. BUdR treatment produced transient moderate myelosuppression that probably resulted from BUdR incorporation into normal marrow cells.

AB - Bromodeoxyuridine (BUdR), a potential radiosensitizing drug, was given by intravenous infusion at 650-1000 mg/m2/day for up to 12 days. In vivo incorporation into human bone marrow was assayed by differential chromatid staining as well as by comparison of in vitro radiation survival curves of granulocyte-macrophage progenitor cells scored at both day 7 and day 14. Although a difference was found in the radiation survival of control (untreated) day-7 progenitor cells (Do = 1.39 Gy) and day-14 progenitor cells (Do = 0.89 Gy), a similar degree of in vitro radiosensitization was found for BUdR-treated bone marrow progenitor cells scored at day 7 and day 14. The culture technique provided a bioassay for the in vivo action of BUdR. BUdR treatment produced transient moderate myelosuppression that probably resulted from BUdR incorporation into normal marrow cells.

UR - http://www.scopus.com/inward/record.url?scp=0021876984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021876984&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 289

EP - 294

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 4

ER -